Clinical practice guidance for Sjögren’s syndrome in pediatric patients (2018) – summarized and updated

References

• Sjögren H. Zur Kenntnis der Keratoconjunctivitis sicca (Keratitis filiformis bei Hypofunktion der Trnendrusen. Acta Ophtalmol. 1933;11(Suppl 2):1–151.
   Google Scholar
• Ramos-Casals M, Brito-Zeron P, Seror R, Bootsma H, Bowman SJ, Dörner T, et al. Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements . Rheumatology (Oxford). 2015;54(12):2230–8.
   PubMed Web of Science ®Google Scholar
• Tomiita M, Saito K, Kohno Y, Shimojo N, Fujikawa S, Niimi H. The clinical features of Sjögren's syndrome in Japanese children. Acta Paediatr JPN. 1997;39(2):268–72.
   PubMedGoogle Scholar
• Cimaz R, Casadei A, Rose C, Bartunkova J, Sediva A, Falcini F, et al. Primary Sjögren syndrome in the paediatric age: a multicentre survey. Eur J Pediatr. 2003;162(10):661–5.
   PubMed Web of Science ®Google Scholar
• Kobayashi I, Okura Y, Ueki M, Tozawa Y, Takezaki S, Yamada M, et al. Evalation of systemic activity of peditatric primary Sjögren’s syndrome by EULAR Sjögren’s syndrome disease activity index (ESSDAI). Mod Rheumatol. 2019;29(1):130–3.
   PubMed Web of Science ®Google Scholar
• Tomiita M. Sjögren’s syndrome in pediatric age (in Japanese). In: Takeuchi T, Kawakami A, Sumita T, editors. Manual for Diagnosis and Treatment of Sjögren’s Syndrome. 3rd ed. Tokyo: Shindantochiryosha; 2018. p. 168–77.
   Google Scholar
• Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.
   PubMed Web of Science ®Google Scholar
• Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K. Revised Japanese criteria for Sjögren’s syndrome (1999): availability and validity. Mod Rheumatol. 2014;14:423–34.
   Google Scholar
• Shiboski SC, Shiboski CH, Criswell LA, Baer AN, Challacombe H, Lanfranchi H, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012;64(4):475–87.
   PubMed Web of Science ®Google Scholar
• Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's Syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheum. 2017;69(1):35–45.
   PubMed Web of Science ®Google Scholar
• Tomiita M. Sjögren’s syndrome (in Japanese). In: Information Center for Specific Pediatric Chronic Diseases, Japan, editors. The Guidance for Diagnosis of Specific Pediatric Chronic Diseases. Tokyo: Shindantochiryosha; 2015. p. 463–5.
   Google Scholar
• Takei S, Kato T. Sjögren’s syndrome in pediatric age (in Japanese). In: Annual report of the research project funded by Health and Labour Sciences Research Grants; Analysis of rare rheumatic diseases using the “Research into Treatment for Specific Pediatric Chronic Diseases” database, 2006; Tokyo; 2007. p. 20–3.
   Google Scholar
• Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, Anaya JM. HLA and Sjögren's syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev. 2012;11(4):281–7. e
   PubMed Web of Science ®Google Scholar
• Fox RI, Pearson G, Vaughan JH. Detection of Epstein-Barr virus-associated antigen and DNA in salivary gland biopsy from patients with Sjögren's syndrome. J Immunol. 1986;137:3162–8.
   PubMed Web of Science ®Google Scholar
• Konttinen YT, Fuellen G, Bing Y, Porola P, Stegaev V, Trokovic N, et al. Sex steroids in Sjögren's syndrome. J Autoimmun. 2012;39(1–2):49–56.
   PubMed Web of Science ®Google Scholar
• Tengnér P, Halse A-K, Haga H-J, Jonsson R, Wahren-Herlenius M. Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjögren's syndrome. Arthritis Rheum. 1998;41(12):2238–48.
   PubMed Web of Science ®Google Scholar
• Matsumoto I, Maeda T, Takemoto Y, Hashimoto Y, Kimura F, Iwamoto I, et al. Anti-amylase functions as a salivary gland-specific self T cell epitope in patients with Sjögren’s syndrome. Int J Mol Med. 1999;3:485–90.
   PubMed Web of Science ®Google Scholar
• Brito-Zeron P, Izmirly PM, Ramos-Casals M, Buyon JP, Khamashta MA. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol. 2015;11(5):301–12.
   PubMed Web of Science ®Google Scholar
• Dawson LJ, Stanbury J, Venn N, Hasdimir B, Rogers SN, Smith PM. Antimuscarinic antibodies in primary Sjögren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. Arthritis Rheum. 2006;54(4):1165–73.
   PubMed Web of Science ®Google Scholar
• Bave U, Nordmark G, Lovgren T, Rönnelid J, Cajander S, Eloranta ML, et al. Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum. 2005;52(4):1185–95.
   PubMed Web of Science ®Google Scholar
• Singh N, Cohen PL. The T cell in Sjogren's syndrome: force majeure, not spectateur. J Autoimmun. 2012;39(3):229–33.
   PubMed Web of Science ®Google Scholar
• Matsumura R, Umemiya K, Kagami M, Tomioka H, Tanabe T, Sugiyama M, et al. Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjögren's syndrome. Clin Exp Rheumatol. 2002;20:791–8.
   PubMedGoogle Scholar
• Nocturne G, Mariette X. Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol. 2015;168(3):317–27.
   PubMed Web of Science ®Google Scholar
• Rabinovich CE. Sjögren Syndrome. In: Kliegman RM, Stanton BMD, Geme JS, Schor NF, editors. Nelson Textbook of Pediatrics. 20th ed. Philadelphia (PA): Saunders; 2015. p. 1192–3.
   Google Scholar
• Houghton K, Malleson P, Cabral D, Petty R, Tucker L. Primary Sjögren’s syndrome in children and adolescents: are proposed diagnostic criteria applicable? J Rheumatol. 2005;32(11):2225–32.
   PubMed Web of Science ®Google Scholar
• Bogdanovic R, Basta-Jovanovic G, Putnik J, Stajic N, Paripovic A. Renal involvement in primary Sjögren syndrome of childhood: case report and literature review. Mod Rheumatol. 2013;23(1):182–9.
   PubMed Web of Science ®Google Scholar
• Kumon K, Satake A, Mizumoto M, Kobayashi I, Ishikawa N. A case of sensory neuropathy associated with childhood Sjögren syndrome. Eur J Pediatr. 2000;159(8):630–1.
   PubMed Web of Science ®Google Scholar
• Kobayashi I, Furuta H, Tame A, Kawamura N, Kojima K, Endoh M, et al. Complications of childhood Sjögren syndrome. Eur J Pediatr. 1996;155(10):890–4.
   PubMed Web of Science ®Google Scholar
• Gottfried JA, Finkel TH, Hunter JV, Carpentieri DF, Finkel RS. Central nervous system Sjögren's syndrome in a child: case report and review of the literature. J Child Neurol. 2001;16(9):683–5.
   PubMed Web of Science ®Google Scholar
• Carvalho DC, Tironi TS, Freitas DS, Kleinpaul R, Talim NC, Lana-Peixoto MA. Sjögren syndrome and neuromyelitis optica spectrum disorder co-exist in a common autoimmune milieu. Arq Neuropsiquiatr. 2014;72(8):619–24.
   PubMed Web of Science ®Google Scholar
• Anaya JM, Ogawa N, Talal N. Sjögren’s syndrome in childhood. J Rheumatol. 1995;22:1152–8.
   PubMed Web of Science ®Google Scholar
• Vermylen C, Meurant A, Noël H, Claus D, Cornu G. Sjögren's syndrome in a child. Eur J Pediatr. 1985;144(3):266–9.
   PubMedGoogle Scholar
• Itoh Y, Imai T, Fujino O, Igarashi T, Fukunaga Y. Subclinical Sjögren's syndrome and anti-Ro/SSA-positive autoimmune fatigue syndrome in children. Mod Rheumatol. 2002;12(3):201–5.
   PubMedGoogle Scholar
• Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A. A longitudinal cohort study of Finnish patients with primary Sjögren’s syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis. 2001;60(5):467–72.
   PubMed Web of Science ®Google Scholar
• Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993;36(3):340–7.
   PubMedGoogle Scholar
• Angusti T, Pilati E, Parente A, Carignola R, Manfredi M, Cauda S, et al. Semi-quantitative analysis of salivary gland scintigraphy in Sjögren’s syndrome diagnosis: a first-line tool. Clin Oral Invest. 2017;21(7):2389–95.
   PubMed Web of Science ®Google Scholar
• Damjanov N, Milic V, Nieto-Gonzalez JC, Janta I, Martinez-Estapiñan L, Serrano B, et al. Multiobserver reliability of ultrasound assessment of salivary glands in patients with established primary Sjögren syndrome. J Rheumatol. 2016;43(10):1858–63.
   PubMed Web of Science ®Google Scholar
• Jonsson MV, Baldini C. Major salivary gland ultrasonography in the diagnosis of Sjögren's Syndrome: a place in the diagnostic criteria? Rheum Dis Clin North Am. 2016;42(3):501–17.
   PubMed Web of Science ®Google Scholar
• Hofauer B, Mansour N, Heiser C, Gahleitner C, Thuermel K, Bas M, et al. Sonoelastographic modalities in the evaluation of salivary gland characteristics in Sjögren’s Syndrome. Ultrasound Med Biol. 2016;42(9):2130–9.
   PubMed Web of Science ®Google Scholar
• Rubin P, Holt JF. Secretory sialography in diseases of the major salivary glands. Am J Roentgenol. 1957;77:575–98.
   Web of Science ®Google Scholar
• Takagi Y, Sumi M, Van Cauteren M, Nakamura T. Fast and high-resolution MR sialography using a small surface coil. J Magn Reson Imaging. 2005;22(1):29–37.
   PubMed Web of Science ®Google Scholar
• Tomiita M, Ueda T, Nagata H, Tanabe E, Shimojo N, Saito K. Usefulness of magnetic resonance sialography in patients with juvenile Sjögren’s syndrome. Clin Exp Rheum. 2005;23:540–4.
   PubMed Web of Science ®Google Scholar
• Schuetz C, Prieur AM, Quaitier P. Sicca syndrome and salivary gland infiltration in children with autoimmune disorders: when can we diagnose Sjögren’s syndrome?. Clin Exp Rheumatol. 2010;28:434–9.
   PubMed Web of Science ®Google Scholar
• Katano K, Kawano M, Koni I, Suigai S, Muro Y. Clinical and laboratory features of anticentromere antibody positive primary Sjögren’s syndrome. J Rheumatol. 2001;23:2238–44.
   Google Scholar
• Bartůnková J, Sedivá A, Vencovský J, Tesar V. Primary Sjögren's syndrome in children and adolescents: proposal for diagnostic criteria. Clin Exp Rheumatol. 1999;17:381–6.
   PubMed Web of Science ®Google Scholar
• Kidder D, Rutherford E, Kipgen D, Fleming S, Geddes C, Stewart GA. Kidney biopsy findings in primary Sjögren syndrome. Nephrol Dial Transplant. 2015;30(8):1363–9.
   PubMed Web of Science ®Google Scholar
• Pérez B, Kraus A, López G, Cifuentes M, Alarcón-Segovia D. Autoimmune thyroid disease in primary Sjögren's syndrome. Am J Med. 1995;99(5):480–4.
   PubMed Web of Science ®Google Scholar
• Yokogawa N, Lieberman SM, Alawi F, Bout-Tabaku S, Guttenberg M, Sherry DD, et al. Comparison of labial minor salivary gland biopsies from childhood Sjögren syndrome and age-matched controls. J Rheumatol. 2014;41(6):1178–82.
   PubMed Web of Science ®Google Scholar
• Yelehe-Okouma M, Czmil-Garon J, Pape E, Petitpain N, Gillet P. Drug-induced aseptic meningitis: a mini-review. Fundam Clin Pharmacol. 2018;32(3):252–60.
   PubMed Web of Science ®Google Scholar
• De Luca R, Trodella M, Vicidomini A, Colella G, Tartaro G. Endoscopic management of salivary gland obstructive diseases in patients with Sjögren's syndrome. J Craniomaxillofac Surg. 2015;43(8):1643–9.
   PubMed Web of Science ®Google Scholar
• Shacham R, Puterman M, Ohana N, Nahlieli O. Endoscopic treatment of salivary glands affected by autoimmune diseases. J Oral Maxillofac Surg. 2011;69(2):476–81.
   PubMed Web of Science ®Google Scholar
• Izumi M, Eguchi K, Nakamura H, Takagi Y, Kawabe Y, Nakamura T. Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjögren’s syndrome. Ann Rheum Dis. 1998;57(8):464–9.
   PubMed Web of Science ®Google Scholar
• Tomiita M, Takei S, Kuwada N, Nonaka Y, Saito K, Shimojo N, et al. Efficacy and safety of orally administered pilocarpine hydrochloride for patients with juvenile-onset Sjögren’s syndrome. Mod Rheumatol. 2010;20(5):486–90.
   PubMed Web of Science ®Google Scholar
• Wu CH, Hsieh SC, Lee KL, Li KJ, Lu MC, Yu CL. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren’s syndrome in Taiwan— a double-blind, placebo-controlled trial. J Formos Med Assoc. 2006;105(10):796–803.
   PubMed Web of Science ®Google Scholar
• Fife RS, Chase WF, Dore RK, Wiesenhutter CW, Lockhart PB, Tindall E, et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch Intern Med. 2002;162(11):1293–300.
   PubMedGoogle Scholar
• Leung KCM, McMillan AS, Wong MCM, Leung WK, Mok MY, Lau CS. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study. Clin Rheumatol. 2008;27(4):429–36.
   PubMed Web of Science ®Google Scholar
• Ichikawa Y, Tokunaga M, Shimizu H, Moriuchi J, Takaya M, Arimori S. Clinical trial of ambroxol (Mucosolvan) in Sjögren’s syndrome. Tokai J Exp Clin Med. 1988;13:165–9.
   PubMedGoogle Scholar
• Ohno S, Suzuki T, Doi Y. A study based on oriental medicine about effectiveness of Bakumondoutou, a Chinese herb, for salivary gland involvement of Sjögren’s syndrome. Ther Res. 1994;15:960–5.
   Google Scholar
• McDonald CC, Kaye SB, Figueiredo FC, Macintosh G, Lockett C. A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye (Lond). 2002;16(5):601–7.
   PubMed Web of Science ®Google Scholar
• Yokoi N, Sonomura Y, Kato H, Komuro A, Kinoshita S. Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren's syndrome. Eye (Lond). 2015;29(9):1204–12.
   PubMed Web of Science ®Google Scholar
• Arimoto A, Kitagawa K, Mita N, Takahashi Y, Shibuya E, Sasaki H. Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in Sjögren syndrome patients with or without punctal occlusions. Cornea 2014;33(8):806–11.
   PubMed Web of Science ®Google Scholar
• Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, et al. Reduction of fatigue in Sjögren syndrome with rituximab: result of a randomized double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67(11):1541–4.,
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot J-M, Perdriger A, Puéchal X, et al. Treatment of primary Sjögren syndrome with rituximab: a randomised trial. Ann Intern Med. 2014;160(4):233–242.
   Web of Science ®Google Scholar
• Meiners PM, Vissink A, Kroese FG, Spijkervet FKL, Smitt-Kamminga NS, Abdulahad WH, et al. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis. 2014;73(7):1393–6.
   PubMed Web of Science ®Google Scholar
• Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, et al. Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74(3):526–31.
   PubMed Web of Science ®Google Scholar
• Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV. Treatment of Sjögren’s syndrome with hydroxychloroquine. Am J Med. 1988;85(4):62–7.
   PubMedGoogle Scholar
• Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of Sjögren’s syndrome with hydroxychloroquine: a retrospective open-label study. Lupus 1996;5(1_suppl):31–6.
   Google Scholar
• Atzeni F, Cazzola M, Benucci M, Di Franco M, Salaffi F, Sarxi-Puttini P. Chronic widespread pain in the spectrum of rheumatological diseases. Best Pract Res Clin Rheumatol. 2011;25(2):165–71.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671–8.
   PubMed Web of Science ®Google Scholar
• Colafrancesco S, Priori R, Gattamelata A, Picarelli G, Minniti A, Brancatisano F, et al. Myositis in primary Sjögren’s syndrome: data from a multicentre cohort. Clin Exp Rheumatol. 2015;33:457–64.
   PubMed Web of Science ®Google Scholar
• Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314–24.
   PubMed Web of Science ®Google Scholar
• Jessop S, Whitelaw DA, Grainge MJ, Jayasekera P. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2017;5:CD002954.
   PubMedGoogle Scholar
• Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol. 1992;127(5):513–8.
   PubMed Web of Science ®Google Scholar
• Kuhn A, Sigges J, Biazar C, Ruland V, Patsinakidis N, Landmann A, et al. Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. Br J Dermatol. 2014;171(3):571–9.
   PubMed Web of Science ®Google Scholar
• Evans RDR, Laing CM, Ciurtin C, Walsh SB. Tubulointerstitial nephritis in primary Sjögren syndrome: clinical manifestations and response to treatment. BMC Musculoskelet Disord. 2016;17:2.
   PubMed Web of Science ®Google Scholar
• Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3):324–30.
   PubMed Web of Science ®Google Scholar
• Radaelli M, Moiola L, Sangalli F, Esposito F, Barcella V, Ferrè L, et al. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler. 2016;22(4):511–9.
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized controlled trial. Lancet Neurol. 2012;11(6):493–502.
   PubMed Web of Science ®Google Scholar
• van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg L, van der Pol WL, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(3):245–53.
   PubMed Web of Science ®Google Scholar
• Yamashita H, Eri T, Ueda Y, Ozaki T, Takahashi H, Tsuno T, et al. Diagnosis and treatment of primary Sjögren syndrome-associated peripheral neuropathy: a six-case series. Mod Rheumatol. 2013;23(5):925–33.
   PubMed Web of Science ®Google Scholar
• Vitali C, Del Papa N. Pain in primary Sjögren's syndrome. Best Pract Res Clin Rheumatol. 2015;29(1):63–70.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia vasculitis. Am J Med. 2015;128(9):950–5.
   PubMed Web of Science ®Google Scholar
• Terrier B, Marie I, Lacraz A, Belenotti P, Bonnet F, Chiche L, et al. Non HCV-related infectious cryoglobulinemia vasculitis: results from the French nationwide CryoVas survey and systematic review of the literature. J Autoimmun. 2015;65:74–81.
   PubMed Web of Science ®Google Scholar
• Visentini M, Tinelli C, Colantuono S, Monti M, Ludovisi S, Gragnani L, et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic review. Autoimmun Rev. 2015;14(10):889–96.
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):843–53.
   PubMed Web of Science ®Google Scholar
• Shirahata A, Ishii E, Eguchi H, Okawa H, Ohta S, Kaneko T, et al. Consensus guideline for diagnosis and treatment of childhood idiopathic thrombocytopenic purpura. Int J Hematol. 2006;83(1):29–38.
   PubMed Web of Science ®Google Scholar
• Newman K, Owlia MB, El-Hemaidi I, Akhtari M. Management of immune cytopenias in patients with systemic lupus erythematosus — old and new. Autoimmun Rev. 2013;12(7):784–91.
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Hosoi H, Kawakita A, Yamamoto S, Akioka S, Hibi S, et al. [Sjögren's syndrome with MALT (mucosa-associated lymphoid tissue) lymphoma in a 13-year-old girl: a case report]. Nihon Rinsho Meneki Gakkai Kaishi. 2000;23(1):49–56.
   PubMedGoogle Scholar
• Zhang X, Zeng X. Severe pulmonary hypertension in pediatric primary Sjögren syndrome: a case report. J Clin Rheumatol. 2007;13(5):276–7.
   PubMed Web of Science ®Google Scholar
• Onji M, Aoyagi Y, Ebinuma H, Ohhira H, Suzuki Y, Zuniya M, et al. Clinical guideline of autoimmune hepatitis 2013 (in Japanese). The Intractable Hepato-Biliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. doi: minds.jcqhc.or.jp/n/med/4/med0196/G0000703/0001
   Google Scholar
• Ishibashi H, Nakamura Y, Ueno Y, Egawa H, Koike K, Komori A, et al. Clinical guideline of primary biliary cirrhosis 2012 (in Japanese). The Intractable Hepato-Biliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Acta Hepatologica Japonica. 2012;53(10):633–86.
   Google Scholar
• Haga HJ, Gjesdal CG, Koksvik HS, Skomsvoll JF, Irgens LM, Ostensen M. Pregnancy outcome in patients with primary Sjögren’s syndrome. a case-control study. J Rheumatol. 2005;32:1734–6.
   PubMed Web of Science ®Google Scholar
• Buyon J, Roubey R, Swersky S, Pompeo L, Parke A, Baxi L, et al. Complete congenital heart block: risk of occurrence and therapeutic approach to prevention. J Rheumatol. 1988;15(7):1104–8.
   PubMed Web of Science ®Google Scholar
• Nield LE, Silverman ED, Taylor GP, Smallhorn JF, Mullen JBM, Silverman NH, et al. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation 2002;105(7):843–8.
   PubMed Web of Science ®Google Scholar
• Moak JP, Barron KS, Hougen TJ, Wiles HB, Balaji S, Sreeram N, et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol. 2001;37(1):238–42.
   PubMed Web of Science ®Google Scholar
• Villain E, Coastedoat-Chalumeau N, Marijon E, Boudjemline Y, Piette JC, Bonnet D. Presentation and prognosis of complete atrioventricular block in childhood, according to maternal antibody status. J Am Coll Cardiol. 2006;48(8):1682–7.
   PubMed Web of Science ®Google Scholar
• Buyon JP, Hiebert R, Copel J, Friedman JCD, Katholi M, Lee LA, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. 1998;31(7):1658–66.
   PubMed Web of Science ®Google Scholar
• Izmirly PM, Saxena A, Kim MY, Wang D, Sahl SK, Llanos C, et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 2011;124(18):1927–35.
   PubMed Web of Science ®Google Scholar
• Eliasson H, Sonesson SE, Sharland G, Granath F, Simpson JM, Carvalho JS, et al. Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation 2011;124(18):1919–26.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Iwamoto M, Sakakibara H, Shigeta H, Hirahara F, Sato K. Treatment of fetal congenital complete heart block with maternal administration of beta-sympathomimetics (terbutaline): a case report. Gynecol Obstet Invest. 2001;52(2):142–4.
   PubMed Web of Science ®Google Scholar
• Gleicher N, Elkayam U. Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: a review of published literature and registered clinical trials. Autoimmun Rev. 2013;12(11):1039–45.
   PubMed Web of Science ®Google Scholar
• NIAMS: Preventive Approach to Congenital Heart Block with Hydroxychloroquin (PACTH study). Available from: http://neonatallupus.com/new-research.htm
   Google Scholar
• Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, et al. EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. Ann Rheum Dis. 2011;70(6):968–72.
   PubMed Web of Science ®Google Scholar
• Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. EULAR Sjögren's Syndrome Disease Activity Index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis. 2010;69(6):1103–9.
   PubMed Web of Science ®Google Scholar
• Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, et al. EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI): a user guide. RMD Open. 2015;1(1):e000022.
   PubMed Web of Science ®Google Scholar
• Iwata N, Miyamae T, Kikuchi M, Kishi T, Hara R, Kaneko U, et al. [Clinical and histological experience of labial lip biopsy in juvenile Sjögren syndrome]). Nihon Rinsho Meneki Gakkai Kaishi. 2009;32(3):195–200.
   PubMedGoogle Scholar